SCHEMBL19632330

SCHEMBL19632330

O=CNc1ccc(F)c(Cl)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.53
RAB9A P51151 4/20 0.53
MEN1 O00255 5/20 0.52
KMT2A Q03164 5/20 0.52
MAPT P10636 4/20 0.52
HTT P42858 3/20 0.52
ALDH1A1 P00352 3/20 0.52
NPSR1 Q6W5P4 1/20 0.52
SLC2A1 P11166 1/20 0.51
TSHR P16473 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.48
TP53 P04637 1/20 0.48
GLA P06280 1/20 0.48
GAA P10253 1/20 0.48
ALOX15 P16050 1/20 0.48
MAPK1 P28482 1/20 0.48
HSD17B10 Q99714 1/20 0.48
LMNA P02545 2/20 0.47
SOS1 Q07889 1/20 0.47
FADS1 O60427 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL90481 1.00 NPC1 (0.53) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL6783917 0.84 RAPGEF4 (0.46) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL241795 0.81 RAB9A (0.46) NPC1RAB9AKMT2AMAPTALDH1A1
SCHEMBL244815 0.81 EPHX1 (0.52) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL6991764 0.76 ALDH1A1 (0.47) MAPTALDH1A1TSHRHSD17B10LMNA
SCHEMBL5046512 0.76 RAPGEF4 (0.50) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL11342814 0.76 MAPT (0.51) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL19444177 0.76 SMN1; SMN2 (0.48) NPC1RAB9AKMT2AMAPTALDH1A1
SCHEMBL19791118 0.76 ALDH1A1 (0.40) NPC1RAB9AKMT2AMAPTALDH1A1
SCHEMBL2658362 0.76 ALDH1A1 (0.40) NPC1RAB9AMEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017198744-A1 NOVEL PYRAZINE COMPOUNDS WITH OXYGEN, SULFUR AND NITROGEN LINKER FOR THE TREATMENT OF INFECTIOUS DISEASES F. HOFFMANN-LA ROCHE AG (CH) 2017-11-23 WO disclosed